# GRAIL

GRAIL is an other based in Menlo Park, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Menlo Park, United States
- **Region:** North America
- **Address:** Menlo Park, CA, United States
- **Founded:** 2015
- **Assets under management:** Undisclosed
- **Website:** grail.com
- **LinkedIn:** https://www.linkedin.com/company/grailai

## Regulatory record

- **CRD number:** 311504
- **Registration status:** Registered
- **Reports private funds:** No
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/311504

## About

Memorable branding for visionary founders. | Grail is a branding agency designed to help founders launch, scale, and evolve at speed. With an agile process tailored to the specific needs of startups, the agency provides branding, messaging, and websites that grow alongside its clients.

## Sectors

- Digital Health
- AI/ML
- Healthcare Services

## Offices

- San Diego, CA, United States
- Princeton, NJ, United States
- Palo Alto, CA, United States
- Kenilworth, NJ, United States
- Shenzhen, China

## People

- Josh Ofman — Chief Executive Officer

## Questions

### Is GRAIL still backed by Illumina?

No. Illumina spun out GRAIL as an independent company in June 2024, after acquiring it in 2021. Illumina no longer holds a controlling stake (per Illumina press release, June 2024).

### What cancer types does Galleri detect?

The Galleri test detects a shared signal from over 50 cancer types, over 45 of which lack standard screening. It is marketed as a laboratory-developed test under CLIA (per GRAIL official communications).

### How is GRAIL's AI/ML work structured?

GRAIL uses machine learning to analyze DNA methylation patterns from a single blood draw. Its algorithms classify the presence and tissue of origin for multiple cancers, refined through a clinical trial of over 40,000 participants (per GRAIL official communications).

### What is the regulatory status of Galleri?

Galleri is available as a CLIA-validated laboratory-developed test. GRAIL is pursuing FDA approval via a Premarket Approval (PMA) pathway, with a pivotal study underway (per GRAIL official communications).

## Related profiles

- [FNB Capital Corporation](https://altss.com/profile/fnb-capital-corporation)
- [Millstone Capital Partners](https://altss.com/profile/millstone-capital-partners)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/grail

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology